{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T17:55:17Z","timestamp":1759773317582},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2015,12,3]],"date-time":"2015-12-03T00:00:00Z","timestamp":1449100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0144136","type":"journal-article","created":{"date-parts":[[2015,12,3]],"date-time":"2015-12-03T18:42:56Z","timestamp":1449168176000},"page":"e0144136","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Nine- to Twelve-Month Anti-Tuberculosis Treatment Is Associated with a Lower Recurrence Rate than 6\u20139-Month Treatment in Human Immunodeficiency Virus-Infected Patients: A Retrospective Population-Based Cohort Study in Taiwan"],"prefix":"10.1371","volume":"10","author":[{"given":"Jann-Yuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsin-Yun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jann-Tay","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Ching","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Chih","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Hsin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Na","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,12,3]]},"reference":[{"key":"ref1","year":"2011"},{"key":"ref2","first-page":"460","article-title":"A controlled trial of six months chemotherapy in pulmonary tuberculosis. Second report: results during the 24 months after the end of chemotherapy. British Thoracic Association","volume":"126","year":"1982","journal-title":"Am Rev Respir Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0041-3879(86)90027-9","article-title":"Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. East and Central African\/British Medical Research Council Fifth Collaborative Study","volume":"67","year":"1986","journal-title":"Tubercle"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1086\/323784","article-title":"Relapse in persons treated for drug-susceptible tuberculosis in a population with high coinfection with human immunodeficiency virus in New York City","volume":"33","author":"CR Driver","year":"2001","journal-title":"Clin Infect Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1086\/375220","article-title":"Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review","volume":"37","author":"EL Korenromp","year":"2003","journal-title":"Clin Infect Dis"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1086\/381675","article-title":"Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use","volume":"38","author":"RE Nettles","year":"2004","journal-title":"Clin Infect Dis"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1164\/rccm.200509-1529OC","article-title":"Treatment outcomes of patients with HIV and tuberculosis","volume":"175","author":"P Nahid","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"ref8","year":"2009"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1164\/rccm.200903-0439OC","article-title":"Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial","volume":"181","author":"S Swaminathan","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"ref10","year":"2011"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jfma.2013.08.010","article-title":"Ensuring the sustainability of the Taiwan National Health Insurance","volume":"113","author":"SK Huang","year":"2014","journal-title":"J Formos Med Assoc"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1038\/bjc.2013.538","article-title":"Urinary tuberculosis is associated with the development of urothelial carcinoma but not renal cell carcinoma: a nationwide cohort study","volume":"109","author":"YC Lien","year":"2013","journal-title":"Taiwan. Brit J Cancer"},{"key":"ref13","year":"2010"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e37978","DOI":"10.1371\/journal.pone.0037978","article-title":"Pulmonary tuberculosis and delay in anti-tuberculous treatment are important risk factors for chronic obstructive pulmonary disease","volume":"7","author":"CH Lee","year":"2012","journal-title":"PLoS One"},{"key":"ref15","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. 14th ed; 2011. Available: http:\/\/www.whocc.no\/filearchive\/publications\/2011guidelines.pdf<\/ext-link>."},{"key":"ref16","author":"KT Luh","year":"2013"},{"key":"ref17"},{"key":"ref18","year":"2010"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1164\/rccm.200603-360OC","article-title":"Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis","volume":"174","author":"WJ Burman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(09)60333-0","article-title":"Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial","volume":"373","author":"MB Conde","year":"2009","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1164\/rccm.200901-0078OC","article-title":"Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis","volume":"180","author":"SE Dorman","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"ref22","first-page":"6","article-title":"Providing HIV care for co-infected tuberculosis patients: a perspective from sub-Saharan Africa","volume":"13","author":"AD Harries","year":"2009","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1086\/496980","article-title":"Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis","volume":"41","author":"M Weiner","year":"2005","journal-title":"Clin Infect Dis"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/429321","article-title":"Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis","volume":"40","author":"M Weiner","year":"2005","journal-title":"Clin Infect Dis"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1056\/NEJM199503233321204","article-title":"Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months","volume":"332","author":"JH Perriens","year":"1995","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1086\/651686","article-title":"Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis","volume":"50","author":"FA Khan","year":"2010","journal-title":"Clin Infect Dis"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jfma.2014.03.003","article-title":"External review of the National Tuberculosis Program and the development of strategy and targets post 2015 in Taiwan","volume":"113","author":"PC Chan","year":"2014","journal-title":"J Formos Med Assoc"},{"key":"ref28","year":"2012"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1378\/chest.14-0918","article-title":"Optimal duration of anti-TB treatment in patients with diabetes: nine or six months?","volume":"147","author":"JY Wang","year":"2015","journal-title":"Chest"},{"key":"ref30","first-page":"437","article-title":"Recurrence of tuberculosis in HIV-1-infected adults treated after rifamycin-based treatment and highly active antiretroviral therapy","volume":"34","author":"CC Hung","year":"2003","journal-title":"J AIDS"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0144136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T12:51:19Z","timestamp":1540039879000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0144136"}},"subtitle":[],"editor":[{"given":"Li-Min","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,12,3]]},"references-count":30,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2015,12,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0144136","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,3]]}}}